Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Crohn Disease Clinical Trial

— MAPUS2  

Official title:

An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03009396
• Other study ID #: RHB-104-04
• Status: Completed
• Phase: Phase 3
• Start date: March 18, 2017
• Est. completion date: August 19, 2019

Study information

• Verified date: February 2021
• Source: RedHill Biopharma Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open label extension to the RHB-104-01 Study.

Description:

An Open Label Phase III Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: August 19, 2019
• Est. primary completion date: November 13, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 76 Years

Eligibility

Inclusion Criteria:

• Signed fully informed consent (ICF) provided as per this protocol.
• Participation in RHB-104-01 for 26 weeks, and a Crohn's Disease Activity Index (CDAI) score of = 150 at Visit Week 26. OR
• More than 26 weeks, with a CDAI =150 at Visit Week 26 and all subsequent visits, and subject is between Week 26 and 52 within 4 weeks (28 days) of site activation (e.g. Subject with CDAI = 249 at week 26 and who is at week 38 at the time of site's activation for RHB-104-04 has a 4-week window to be enrolled in the open label study via the Optional Screening Visit)
• Current treatment with at least one of the following therapies which may be discontinued by the investigator as clinically indicated after 8 weeks of open label

RHB-104 treatment:

• Oral 5-acetyl salicylic acid (5-ASA) compounds
• Azathioprine or 6-mercaptopurine (6-MP) or methotrexate
• Infliximab or adalimumab OR Current treatment with corticosteroid therapy which must begin tapering after 4 weeks of treatment with open label RHB-104 (Refer to Appendix 13)
• White blood cell count = 3.5x109 at screening (RHB-104-01 Visit Week 26 visit or Optional Screening visit)
• Subject agrees to use the following effective contraceptive methods
• diaphragm, cervical cap, contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository
• IUD (intrauterine device) /IUS (intrauterine system)
• progestogen injection (Depo-Provera®) throughout the study and for at least 6 weeks after last study drug administration, unless subject or partner of subject is post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation, or has had a vasectomy. Post-menopausal is defined as having experienced 12 consecutive months without menstruation. In regions where local regulatory contraceptive requirements differ, the ICF (Informed Consent Form) will reflect local policies.

Exclusion Criteria:

1. Positive stool results for C. difficile.

2. Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or optometrist.

3. Treatment with any medication that causes QT prolongation or Torsades de Pointes, including but not limited to: amiodarone, amitriptyline, astemizole, cisapride, citalopram dose greater than 20 mg/day, dihydroergotamine, disopyramide, dofetilide, dronedarone, ergotamine, ibutilide, ondansetron or other 5-HT3 (5-hydroxytryptamine three) receptor antagonists, pimozide, procainamide, quinidine, quinine, quinolones, ranolazine, risperidone, sotalol, terfenadine and tolterodine. QT prolonging drugs may be referenced at the CredibleMeds® web site: https://crediblemeds.org/index.php/drugsearch/

4. Treatment with the following CYP3A4 interactive medications: alfentanyl, alprazolam, amlodipine, anti-retroviral agents, apixaban, aprepitant, aripiprazole, atorvastatin, boceprevir, buspirone, carbamazepine, carvedilol, colchicine, cyclosporine, digoxin, diltiazem, estrogens, felodipine, fluconazole, fluvoxamine, grapefruit juice, haloperidol, ketoconazole, lovastatin, lurasidone, metoprolol, nefazodone, nifedipine, nisoldipine, nitrendipine, propranol, roflumilast, simvastatin, St. John's wort, and voriconazole.

5. Any evidence of any newly diagnosed significant hematological, hepatic, renal, cardiac, pulmonary, metabolic, neurological, psychiatric or other disease (e.g. porphyria) that might interfere with subject's ability to safely enter and or complete the study requirements.

6. Females who have a positive pregnancy test or are lactating.

7. Refusal to sign the study informed consent form.

8. Inability to be able to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.

9. Clinically significant abnormalities of hematology or biochemistry as confirmed by repeat testing based on investigator's discretion, including but not limited to, elevations greater than 2 times the upper limit of normal of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) or creatinine clearance less than 60 ml/min at screening via estimated Cockcroft-Gault formula: Creatinine Clearance = [140 - age in years] * weight (kg) / 72 * Serum Creatinine (mg/dl) [multiply estimated rate by 0.85 for women], using actual body weight.

10. QTcF (shortening of the QT interval in the heart rate) >450ms in males and QTcF>460ms in females, bundle branch block, or major ST or T wave abnormalities that make the assessment of the QT impossible.

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Drug:
• RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks

Locations

Country	Name	City	State
Canada	Discovery Clinical Services Ltd., 601 A Discovery St.	Victoria	British Columbia
Czechia	Gastroenterologie s.r.o. Manesova 646	Hradec Kralove
Czechia	Hepato-Gastroenterologie HK, s.r.o., Hradecka poliklinika III Trida Edvarda Benese 1549/34	Hradec Králové
Israel	Ha'Emek Medical Center, Institute of Gastroenterology and Liver diseases, 21 Yitshak Rabin Boulevard	Afula
Israel	Gastroenterology Institute, Division of Medicine, Hadassah - Hebrew University Medical Center POB 12000	Jerusalem
Israel	Meir Medial Center, 59 Tchemacovsky St.	Kfar-Saba
New Zealand	Christchurch Hospital, 2 Riccarton Rd.	Christchurch	Canterbury
New Zealand	Waikato Hospital, Department of Gastroenterology, Level B1, Menzies Building, Pembroke Street	Hamilton	Waikato
Poland	NZOZ Specjalistyczne Centrum Gastrologii GASTROMED, Wiejska 81	Bialystok
Poland	Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSW W Gdansku Oddzial Gastroenterologiczny, Ul. Kartuska 4/6	Gdansk
Poland	UNICARDIA Specjalistyczne Centrum Leczenia Chorob Serca i Naczyn & UNIMEDICA. Specjalistyczne Centrum Medyczne Sp. z o.o., Kluczborska 15	Kraków
Poland	Wojewodzki Szpital Kliniczny w Olsztynie Oddzial Gastroenterologiczny, Zolnierska 18	Olsztyn
Poland	EuroMedis sp. z.o.o., Al. Powstancow Wielkopolskich 33a	Szczecin
Poland	Centralny Szpital Kliniczny MSW w Warszawie. Klinika Chorob Wewnetrznych i Gastroenterologii, Woloska 137,	Warsaw
Poland	ARS MEDICA s.c., Powstancow Slaskich 56A/2	Wroclaw
Serbia	Clinical Department of Gastroenterology and Hepatology Clinic for Internal Diseases Clinical Hospital Center Zvezdara Dimitrija Tucovica 161	Belgrade
Serbia	Department of Gastroenterology and Hepatology, Clinical Hospital Center Zemun, Vukova 9	Belgrade
Serbia	Center for Gastroenterohepatology, Clinic for Internal Medicine, Clinical Center Kragujevac, Zmaj Jovina 30	Kragujevac
United States	Commonwealth Clinical Studies, 189 Quincy St.	Brockton	Massachusetts
United States	ClinSearch 6035 Shallowford Road Suite 109	Chattanooga	Tennessee
United States	Chevy Chase Clinical Research, 5550 Friendship Blvd.	Chevy Chase	Maryland
United States	Gastrointestinal Specialists of Georgia PC 711 Canton Rd. #300	Marietta	Georgia
United States	Digestive Care Associates, Inc., 1000 Laurel Street	San Carlos	California
United States	Cotton-O'Neil Clinical Research Center, 720 SW Lane St.	Topeka	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
RedHill Biopharma Limited

Countries where clinical trial is conducted

United States,  Canada,  Czechia,  Israel,  New Zealand,  Poland,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Increase in Milliseconds (ms) QT Wave	The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report).	week 52
Primary	Number of Patients in Remission at Week 16	The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points.; Lower CDAI scores indicate a better outcome.	Week 16
Secondary	Response at Week 16	Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome.	Week 16
Secondary	The Number of Weeks for Patients to Achieve Remission	[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment.	Baseline through week 52
Secondary	Number of Weeks the Patients Are in Remission	Duration of remission is defined as the number of weeks the subject is in remission (CDAI score < 150). It is calculated as the first date following remission at which CDAI is =150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.	Baseline through week 52
Secondary	Number of Weeks to Achieve Response	[Date of first observed response (a reduction from baseline of = 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.	Baseline through week 52
Secondary	Number of Weeks the Patients Are in Response.	Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of = 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is <100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.	Baseline through week 52
Secondary	Durable Remission Week 16 Through Week 52	When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52.	Week 16 through week 52

External Links

•   RedHill home page